SKLB-197 |
| Katalog-Nr.GC64539 |
SKLB-197 zeigte einen IC50-Wert von 0,013 μM gegen ATR, aber sehr schwache oder keine AktivitÄt gegen andere 402-Proteinkinasen. Es zeigte sowohl in vitro als auch in vivo eine starke AntitumoraktivitÄt gegen ATM-defiziente Tumore.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2713577-16-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SKLB-197 showed an IC50 value of 0.013 μM against ATR but very weak or no activity against other 402 protein kinases. It displayed potent antitumor activity against ATM-deficent tumors both in vitro and in vivo.
[1]. Bin H,et al. Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in vitro and in vivo. Eur J Med Chem. 2022 Feb 12;232:114187
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *